Arrhythmias & electrophysiology
Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation
Primary result · NT-proBNPResult — go to the resultBetween-group difference 409.8 pg/mL 95% CI 230.6–589.1Authors' conclusion
Diltiazem reduced NT-proBNP levels and improved rhythm-related symptoms. Metoprolol increased peptide levels but had no impact on symptoms despite similar heart rate reduction.
Study context
- Population
- Men and women with permanent atrial fibrillation (AF) and preserved LV systolic functionmean age 71 ± 7 years, 28 women
- Participants
- 93 men
- Comparison
- Diltiazem vs metoprolol for rate control
- Primary endpoint
- NT-proBNP level
- Follow-up
- 6 months
Primary result
NT-proBNP
Between-group difference
409.8 pg/mL
95% CI 230.6–589.1
P < 0.001
Diltiazemvs Metoprolol
between-group difference 409.8 pg/mL (95% CI 230.6–589.1); P < 0.001
As reported in the abstract
Secondary outcomes
Rhythm-related symptoms · 6 months
- Diltiazem significantly reduced rhythm-related symptoms vs baseline; no change with metoprolol
Heart rate and exercise capacity
- Similar effects with diltiazem and metoprolol
Original publication
Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. Published 3 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →